HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on United Therapeutics (NASDAQ:UTHR) and maintained a price target of $300.
August 04, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
United Therapeutics (NASDAQ:UTHR) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $300.
The reiteration of a 'Buy' rating and a high price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for United Therapeutics. This could potentially lead to an increase in investor confidence and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100